Pelvic pain in transgender men taking testosterone: Assessing the risk of ovarian cancerHarris, Miles MS, BSN; Kondel, Lauren MS, BSN, FNP-BC; Dorsen, Caroline PhD, MSN, FNPThe Nurse Practitioner: July 15th, 2017 - Volume 42 - Issue 7 - p 1–5 doi: 10.1097/01.NPR.0000520423.83910.e2 Online exclusive Buy Abstract Author InformationAuthors Article MetricsMetrics Abstract: Some guidelines on care for transgender men taking testosterone recommend oophorectomy to prevent ovarian cancer, while others recommend following guidelines for females. A review of the literature finds no strong evidence that transgender men are at increased risk for ovarian cancer. In transgender men taking testosterone without other risk factors, oophorectomy to prevent cancer is unnecessary. Miles Harris is an NP at the Comprehensive Health Program, Mount Sinai Institute for Advanced Medicine, New York, N.Y. Lauren Kondel is an NP at New York University, New York, N.Y. Caroline Dorsen is an assistant professor at Meyers College of Nursing, New York University, New York, N.Y. The authors have disclosed that they have no financial relationships related to this article. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.